Navigation Links
Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
Date:5/19/2009

MADISON, N.J., May 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has commenced a cash tender offer to purchase up to $200 million aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are described in the Offer to Purchase dated May 19, 2009 and related Letter of Transmittal.

The following table summarizes terms material to the determination of the total consideration to be received in the offer:

                                   Aggregate
                                   Principal
       CUSIP       Title of         Amount          Acceptance Priority
       Number      Security       Outstanding              Level
       ------      --------       ------------      -------------------

     74834LAK6      5.125%        $400,000,000               1
                    Senior
                   Notes due
                     2010

     74834LAE0       7.50%        $275,000,000               2
                    Senior
                   Notes due
                     2011


                  Reference    Bloomberg                     Early
       CUSIP      Treasury     Reference    Fixed Spread     Tender
       Number     Security       Page        (bps) (1)      Premium (2)
       ------     ---------    ---------    ------------    -----------

     74834LAK6   0.875% due      PX1           + 225          $30.00
                  April 30,
                    2011

     74834LAE0   0.875% due      PX1           + 365          $30.00
                  April 30,
                    2011

(1) Includes the Early Tender Premium per $1,000 principal amount of Notes for each Series (the "Early Tender Premium") as set forth in this table.

(2) Per $1,000 principal amount of Notes tendered and validly accepted.

The tender offer will expire at midnight, New York City time, on June 16, 2009, unless extended (the "Expiration Date").

Holders of Notes who validly tender and do not validly withdraw their Notes at or prior to 5:00 p.m., New York City time, on June 2, 2009 (the "Early Tender Date"), will receive the Total Tender Offer Consideration (as defined in the Offer to Purchase), which includes an Early Tender Premium of $30 per $1,000 in principal amount of Notes tendered and validly accepted. Holders of Notes who validly tender their Notes after the Early Tender Date and at or before midnight, New York City time, on the Expiration Date will be eligible to receive only the Late Tender Offer Consideration (as defined in the Offer to Purchase) per $1,000 principal amount of Notes tendered by such Holders that are accepted for purchase, which is equal to the applicable Total Tender Offer Consideration minus the Early Tender Premium.

The amount of each series of Notes purchased in the tender offer will be determined in accordance with the Tender Cap and the Acceptance Priority Levels set forth above, as described in the Offer to Purchase and related Letter of Transmittal.

Holders may withdraw tenders of Notes at or prior to the Early Tender Date, but except as otherwise provided in the Offer to Purchase, not thereafter.

Settlement of the tender offer is expected to occur on the second business day following the Expiration Date.

Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and Mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and to serve as the information agent for the tender offer.

For additional information regarding the terms of the tender offer, please contact: Banc of America Securities LLC at (888) 292-0070 (toll free) or (980) 388-4603 (collect).

Requests for documents and questions regarding the tendering of Notes may be directed to Global Bondholder Services Corporation, at (866) 470-3800 (toll free).

About Quest Diagnostics

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care. Additional company information is available at www.QuestDiagnostics.com.

The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, changes in government regulations, changing relationships with customers, payers, suppliers and strategic partners and other factors discussed in "Business" in Part I, Item 1, "Risk Factors" and "Cautionary Factors that May Affect Future Results" in Part I, Item 1A, "Legal Proceedings" in Part I, Item 3, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Part II, Item 7 and "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A in the company's 2008 Annual Report on Form 10-K and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk" in the company's 2009 Quarterly Report on Form 10-Q and other items throughout the Form 10-K and the company's 2009 Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.


'/>"/>
SOURCE Quest Diagnostics Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Quest Diagnostics to Speak at the Deutsche Bank 34th Annual Healthcare Conference
2. Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online
3. "Farrah's Law" Grants Fawcett's Last Request
4. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
5. Quest Diagnostics Declares Quarterly Cash Dividend
6. Sen. Max Baucus: Answer 10 Questions About Mandatory Purchase of Health Insurance Including Why the Public Was Excluded From Todays Committee Meeting
7. Heinz Family Philanthropies (www.heinzfamily.org) Release New Facts About Cards, Highlighting Questions Families Should Ask About Long-Term Care -- 10 Questions to Answer... (www.tenquestionstoanswer.org)
8. NCPA Briefing Raises Questions About Trustees Annual Report
9. When to get your bone density measured -- that is the question
10. BANDIT Questions the H1N1 Media Craze, and Tries to Give AIDS Its Sexy Back!
11. Quest Diagnostics Announces Annual Shareholders Meeting Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... The ... , a program to critically evaluate and rank health-focused applications and connected devices ... to provide independent, unbiased and accurate information to help accelerate patient and provider ...
(Date:4/30/2016)... (PRWEB) , ... April 30, 2016 , ... Orlando-based Maximized ... as they go for gold in Rio. Under the care of Maximized Living ... golds! , In an unprecedented showing, Maximized Living is sending the largest contingent of ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... notified by the Accreditation Council for Graduate Medical Education (ACGME) that it has ... This is the first accreditation of three residency programs that Memorial is currently ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... ... advocating optimistic healthcare awareness and author of best seller "LOVE, MEDICINE and MIRACLES") ... Radio Monday, May 2, 2016 and podcasted thereafter . Dr. Bernie Siegel, ...
(Date:4/29/2016)... ... 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing in ... physicians has been invited to be a featured speaker at the Texas Society of ... April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and rehabilitation ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... Switzerland , April 27, 2016 ... AG announced the launch of a Phase 2 clinical ... residual hearing in patients undergoing cochlear implantation (CI) surgery. ... recruiting patients in Germany and ... into the middle ear at the time of surgery. ...
(Date:4/26/2016)... 26, 2016 Hill-Rom Holdings, Inc. (NYSE: ... at the Deutsche Bank 41 st Annual Health Care ... You are invited to listen to the live ... access it directly at http://edge.media-server.com/m/p/mr4uxgas . A recorded replay ... of the live event and accessible at the links above ...
(Date:4/26/2016)... , April 27, 2016 Research ... "Global Molecular Diagnostics Market 2016-2020" report to their ... , ,The global molecular diagnostics market is projected to ... 2016-2020. Molecular diagnostics is a technique that ... the molecular level to detect changes in biochemical pathways. ...
Breaking Medicine Technology: